NASDAQ:CRGX CARGO Therapeutics (CRGX) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free CRGX Stock Alerts $19.98 -0.40 (-1.96%) (As of 10:13 AM ET) Add Compare Share Share Today's Range$19.44▼$20.3450-Day Range$18.28▼$32.2352-Week Range$13.14▼$33.92Volume14,324 shsAverage Volume257,297 shsMarket Capitalization$786.59 millionP/E RatioN/ADividend YieldN/APrice Target$29.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get CARGO Therapeutics alerts: Email Address CARGO Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside48.5% Upside$29.67 Price TargetShort InterestBearish13.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($5.60) to ($5.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.44 out of 5 starsMedical Sector634th out of 905 stocksBiological Products, Except Diagnostic Industry103rd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCARGO Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCARGO Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about CARGO Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.21% of the float of CARGO Therapeutics has been sold short.Short Interest Ratio / Days to CoverCARGO Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in CARGO Therapeutics has recently decreased by 5.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCARGO Therapeutics does not currently pay a dividend.Dividend GrowthCARGO Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRGX. Previous Next 2.0 News and Social Media Coverage News SentimentCARGO Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CARGO Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added CARGO Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.38% of the stock of CARGO Therapeutics is held by insiders.Percentage Held by Institutions93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CARGO Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CARGO Therapeutics are expected to decrease in the coming year, from ($5.60) to ($5.65) per share.Price to Book Value per Share RatioCARGO Therapeutics has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CARGO Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About CARGO Therapeutics Stock (NASDAQ:CRGX)CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Read More CRGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRGX Stock News HeadlinesMay 9, 2024 | finance.yahoo.comIs There An Opportunity With CARGO Therapeutics, Inc.'s (NASDAQ:CRGX) 21% Undervaluation?May 2, 2024 | americanbankingnews.comCARGO Therapeutics, Inc. (NASDAQ:CRGX) Short Interest Down 5.3% in AprilMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 1, 2024 | americanbankingnews.comCARGO Therapeutics, Inc.'s Lock-Up Period Set To Expire on May 8th (NASDAQ:CRGX)April 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for CARGO Therapeutics on Robust Trial Progress and Strong Market PotentialApril 18, 2024 | finance.yahoo.comCARGO Therapeutics, Inc. (CRGX)April 17, 2024 | investing.comCARGO Therapeutics appoints new board memberApril 15, 2024 | globenewswire.comCARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of DirectorsMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.March 28, 2024 | bizjournals.comReal Estate Deals: Cargo leases San Carlos biotech spaceMarch 22, 2024 | finanznachrichten.deCargo Therapeutics, Inc.: CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | markets.businessinsider.comCARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | globenewswire.comCARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | finance.yahoo.comSpyre Therapeutics, Inc. (SYRE)February 29, 2024 | globenewswire.comCARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare ConferenceFebruary 24, 2024 | msn.comCARGO Therapeutics (CRGX) Price Target Increased by 9.80% to 28.56February 22, 2024 | benzinga.comCargo Therapeutics Stock (NASDAQ:CRGX) Dividends: History, Yield and DatesFebruary 6, 2024 | finance.yahoo.com3 New Stock Listings That Can Deliver Multibagger ReturnsJanuary 28, 2024 | seekingalpha.comCargo Therapeutics: High Venture Interest But Still Early Days For This CAR-T PlayerJanuary 11, 2024 | seekingalpha.comCRGX CARGO Therapeutics, Inc.January 3, 2024 | finance.yahoo.comCARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | bizjournals.comAlexandria's San Carlos project lands Bay Area's latest biotech IPO company as big tenantDecember 14, 2023 | finanznachrichten.deCargo Therapeutics, Inc.: CARGO Therapeutics Reports Business Updates and Third Quarter 2023 ResultsDecember 13, 2023 | finance.yahoo.comCARGO Therapeutics Reports Business Updates and Third Quarter 2023 ResultsDecember 11, 2023 | wsj.comCARGO Therapeutics Inc.December 10, 2023 | benzinga.comCargo Therapeutics Stock (NASDAQ:CRGX) Insider TradesDecember 7, 2023 | morningstar.comCargo Therapeutics Inc CRGXSee More Headlines Receive CRGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CARGO Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/09/2024Next Earnings (Estimated)6/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CRGX Previous SymbolNASDAQ:CRGX CUSIPN/A CIK1966494 Webcargo-tx.com Phone650-379-6143FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$29.67 High Stock Price Target$34.00 Low Stock Price Target$23.00 Potential Upside/Downside+45.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio19.35 Quick Ratio19.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.84 per share Price / Book2.07Miscellaneous Outstanding Shares39,369,000Free Float38,826,000Market Cap$802.34 million OptionableN/A BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Gina Chapman (Age 56)President, CEO & Director Comp: $755.35kDr. Crystal L. Mackall M.D. (Age 63)Co-Founder Comp: $160kDr. Shishir Gadam Ph.D. (Age 57)Chief Technical Officer Comp: $674.03kDr. Robbie Majzner M.D.Founder & Chair of Scientific Advisory BoardMs. Nancy Goodman J.D.FounderDr. Louai LabaniehFounderMr. Anup Radhakrishnan (Age 44)CFO, Secretary & Chief Business Officer Dr. Corinne D. Epperly M.D. (Age 46)M.P.H., Chief Operating Officer Mr. Faisal Shawwa M.B.A.Senior Vice President of Finance & AccountingDr. Michael Ports Ph.D. (Age 43)Chief Scientific Officer More ExecutivesKey CompetitorsMesoblastNASDAQ:MESOREGENXBIONASDAQ:RGNXImmaticsNASDAQ:IMTXBioCryst PharmaceuticalsNASDAQ:BCRXHilleVaxNASDAQ:HLVXView All CompetitorsInsiders & InstitutionsSwiss National BankBought 28,500 shares on 5/7/2024Ownership: 0.072%BNP Paribas Financial MarketsBought 10,664 shares on 5/1/2024Ownership: 0.027%Wellington Management Group LLPBought 1,711,502 shares on 3/5/2024Ownership: 4.154%Perceptive Advisors LLCBought 3,436,600 shares on 2/26/2024Ownership: 8.339%RTW Investments LPBought 5,175,832 shares on 2/14/2024Ownership: 12.560%View All Insider TransactionsView All Institutional Transactions CRGX Stock Analysis - Frequently Asked Questions Should I buy or sell CARGO Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CARGO Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRGX shares. View CRGX analyst ratings or view top-rated stocks. What is CARGO Therapeutics' stock price target for 2024? 4 equities research analysts have issued 1-year price objectives for CARGO Therapeutics' shares. Their CRGX share price targets range from $23.00 to $34.00. On average, they expect the company's stock price to reach $29.67 in the next twelve months. This suggests a possible upside of 48.5% from the stock's current price. View analysts price targets for CRGX or view top-rated stocks among Wall Street analysts. How have CRGX shares performed in 2024? CARGO Therapeutics' stock was trading at $23.15 at the beginning of 2024. Since then, CRGX shares have decreased by 13.7% and is now trading at $19.98. View the best growth stocks for 2024 here. Are investors shorting CARGO Therapeutics? CARGO Therapeutics saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 3,400,000 shares, a drop of 5.3% from the March 31st total of 3,590,000 shares. Based on an average trading volume of 303,200 shares, the days-to-cover ratio is presently 11.2 days. Approximately 13.2% of the company's stock are sold short. View CARGO Therapeutics' Short Interest. When is CARGO Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 20th 2024. View our CRGX earnings forecast. How were CARGO Therapeutics' earnings last quarter? CARGO Therapeutics, Inc. (NASDAQ:CRGX) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($1.49) earnings per share for the quarter, topping analysts' consensus estimates of ($1.62) by $0.13. When did CARGO Therapeutics IPO? CARGO Therapeutics (CRGX) raised $281 million in an IPO on Friday, November 10th 2023. The company issued 18,750,000 shares at $15.00 per share. When did the company's lock-up period expire? CARGO Therapeutics' lock-up period expired on Wednesday, May 8th. CARGO Therapeutics had issued 18,750,000 shares in its IPO on November 10th. The total size of the offering was $281,250,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period. Who are CARGO Therapeutics' major shareholders? CARGO Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Swiss National Bank (0.07%) and BNP Paribas Financial Markets (0.03%). View institutional ownership trends. How do I buy shares of CARGO Therapeutics? Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRGX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CARGO Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
